Gapping down
In reaction to disappointing earnings/guidance: VSH -13.1%, AMAG -11.3%, QLYS -11%, NMM -10.4%, AQXP -10.3%, TNET -9.3%, S -8.5%, CGNX -8.4%, CAR -7.7%, EXLP -7.4%, DWRE -7.3%, ADM -7.3%, FIT -7.2%, TASR -6.5%, CGEN -6.2%, UBS -6.1%, AEIS -5.3%, ANIP -5.1%, UNXL -5%, OLN -4.8%, UNVR -4.8%, ODP -4.4%, GGP -3.9%, DBVT -3.6%, ARIA -3.6%,AXLL -3.5%, K -3.3%, AIG -2.9%, AXON -2.8%, NCLH -2.8%, VGR -2.7%, FTR -2.5%, DNOW -2.2%, MDCO -2.2%, ZIOP -2%, AMC -1.8%, OHI -1.5%, EMR -1.4%, KMT -1.3%, KONA -1.2%, TDOC -1%
M&A news: EJ -6.1% (receives revised non-binding 'going private' proposal for $6.64/share)
Other news: ASC -12% ( announces a 4 mln share secondary offering by selling stockholder, GA Holdings), AQXP -10.3% (reports results from Phase 2 KINSHIP trial with AQX-1125; trial did not meet primary endpoint), AREX -5.4% (to be removed from the S&P SmallCap 600), SUI -3.7% (prices offering of 3,250,000 shares of common stock at $65.00 per share), HTZ-3.3% (following CAR results), FCAU -1.8% (reported October 2015 US sales), GSK -1.4% (Pfizer (PFE) spoke to GSK about M&A deal before talks with Allergan (AGN), according to FT), AEG -0.8% (receives designation as 'systemically important' by the Financial Stability Board)
Analyst comments: CNX -3.2% (downgraded to Sell from Hold at Deutsche Bank), MDLY -2.4% (downgraded to Mkt Perform at FBR Capital), NVDA -0.7% (downgraded to Hold at Needham)
.
In reaction to disappointing earnings/guidance: VSH -13.1%, AMAG -11.3%, QLYS -11%, NMM -10.4%, AQXP -10.3%, TNET -9.3%, S -8.5%, CGNX -8.4%, CAR -7.7%, EXLP -7.4%, DWRE -7.3%, ADM -7.3%, FIT -7.2%, TASR -6.5%, CGEN -6.2%, UBS -6.1%, AEIS -5.3%, ANIP -5.1%, UNXL -5%, OLN -4.8%, UNVR -4.8%, ODP -4.4%, GGP -3.9%, DBVT -3.6%, ARIA -3.6%,AXLL -3.5%, K -3.3%, AIG -2.9%, AXON -2.8%, NCLH -2.8%, VGR -2.7%, FTR -2.5%, DNOW -2.2%, MDCO -2.2%, ZIOP -2%, AMC -1.8%, OHI -1.5%, EMR -1.4%, KMT -1.3%, KONA -1.2%, TDOC -1%
M&A news: EJ -6.1% (receives revised non-binding 'going private' proposal for $6.64/share)
Other news: ASC -12% ( announces a 4 mln share secondary offering by selling stockholder, GA Holdings), AQXP -10.3% (reports results from Phase 2 KINSHIP trial with AQX-1125; trial did not meet primary endpoint), AREX -5.4% (to be removed from the S&P SmallCap 600), SUI -3.7% (prices offering of 3,250,000 shares of common stock at $65.00 per share), HTZ-3.3% (following CAR results), FCAU -1.8% (reported October 2015 US sales), GSK -1.4% (Pfizer (PFE) spoke to GSK about M&A deal before talks with Allergan (AGN), according to FT), AEG -0.8% (receives designation as 'systemically important' by the Financial Stability Board)
Analyst comments: CNX -3.2% (downgraded to Sell from Hold at Deutsche Bank), MDLY -2.4% (downgraded to Mkt Perform at FBR Capital), NVDA -0.7% (downgraded to Hold at Needham)
.